Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 8, 2014, Pages

  Wang, Na ^a   Xu, Dawei ^b   Sofiadis, Anastasios ^a   Höög, Anders ^a   Vukojević, Vladana ^b   Bäckdahl, Martin ^a,b   Zedenius, Jan ^a,b   Larsson, Catharina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; HEK293 CELLS; HELA CELLS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET; SURVIVAL ANALYSIS; TELOMERASE; TELOMERE; TELOMERE HOMEOSTASIS; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84905826777     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1158     Document Type: Article

References (40)

1. Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol. 2000;1:72-76.
2. GreiderCW.Telomeres and senescence: the history, the experiment, the future. Curr Biol. 1998;8:R178-181.
3. Gisselsson D, Jonson T, Petersén A, et al. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc Natl Acad Sci U S A. 2001;98:12683-12688.
4. Wu X, Amos CI, Zhu Y, et al. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst. 2003;95:1211-1218.
5. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet. 2001;10:677-685.
6. Bryan TM, Marusic L, Bacchetti S, Namba M, Reddel RR. The telomere lengthening mechanism in telomerase-negative immortal humancells does not involve the telomeraseRNAsubunit.HumMol Genet. 1997;6:921-926.
7. Reddel RR, Bryan TM, Murnane JP. Immortalized cells with no detectable telomerase activity. A review. Biochemistry (Mosc). 1997;62:1254-1262.
8. DeLellis RA. 2004 Pathology and genetics of tumours of endocrine organs. Lyon: Lyon : IARC Press, 2004.
9. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565-612.
10. Zedenius J, Wallin G, Hamberger B, Nordenskjöld M, Weber G, Larsson C. Somatic andMEN2Ade novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s. Hum Mol Genet. 1994;3:1259-1262.
11. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110: 6021-6026.
12. Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20:603-610.
13. Landa I, Ganly I, Chan TA, et al. Frequent somatic TERT promoter mutations in thyroid cancer: Higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98:E1562-E1566.
14. Vinagre J, Almeida A, Populo H, et al. Frequency ofTERTpromoter mutations in human cancers. Nat Commun. 2013;4:2185.
15. Liu T, Wang N, Cao J, et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 2013 Oct 21, doi:10.1038/onc.2013.446.
16. WangY, Kowalski J, Tsai HL, et al. Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms. Thyroid. 2008;18:1055-1063.
17. Kilian A, Bowtell DD, Abud HE, et al. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet. 1997;6: 2011-2019.
18. Fan Y, Liu Z, Fang X, et al. Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activitytween normal and malignant renal tissues. Clin Cancer Res. 2005; 11:4331-4337.
19. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res. 1998;58:4168-4172.
20. Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR. The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia. 2000;2:426-432.
21. Hisatomi H, Ohyashiki K, Ohyashiki JH, et al. Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene. Neoplasia. 2003;5:193-197.
22. Kim NW, WuF. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res. 1997;25:2595-2597.
23. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30:e47.
24. Henson JD, Hannay JA, McCarthy SW, et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res. 2005;11:217-225.
25. Nugent CI, Lundblad V. The telomerase reverse transcriptase: components and regulation. Genes Dev. 1998;12:1073-1085.
26. Bockhorn M, Frilling A, Clauer U, Hertl M, Broelsch CE. Telomerase activity in neuroendocrine tumors. Int J Surg Investig. 2000; 2:219-225.
27. Stadler G, Wieser M, Streubel B, et al. Low telomerase activity: Possible role in the progression of human medullary thyroid carcinoma. Eur J Cancer. 2008;44:866-875.
28. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998; 279:349-352.
29. Blackburn EH. Structure and function of telomeres. Nature. 1991; 350:569-573.
30. Orlando C, Gelmini S. Telomerase in endocrine and endocrine-dependent tumors. J Steroid Biochem Mol Biol. 2001;78:201-214.
31. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93:682-687.
32. Mian C, Pennelli G, Barollo S, et al. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol. 2011;164:971-976.
33. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet. 2010;11:319-330.
34. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med. 1997;3:1271-1274.
35. Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. Oncogene. 2002;21: 598-610.
36. Fasching CL, Bower K, Reddel RR. Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies. Cancer Res. 2005;65:2722-2729.
37. Marciniak RA, Cavazos D, Montellano R, Chen Q, Guarente L, Johnson FB. A novel telomere structure in a human alternative lengthening of telomeres cell line. Cancer Res. 2005;65:2730-2737.
38. Brachner A, Sasgary S, Pirker C, et al. Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis- derived human non-small cell lung cancer cell line: effect of ectopic hTERT. Cancer Res. 2006;66:3584-3592.
39. CeroneMA, Autexier C, Londoño -Vallejo JA, Bacchetti S.Ahuman cell line that maintains telomeres in the absence of telomerase and of key markers of ALT. Oncogene. 2005;24:7893-7901.
40. Capezzone M, Marchisotta S, Cantara S, Pacini F. Telomeres and thyroid cancer. Curr Genomics. 2009;10:526-533.